PMV PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
PMV PHARMACEUTICALS, INC. (PMVP) reported Other Comprehensive Income (Loss), Net of Tax of -$67.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$67.00K.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$99.00K.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$7.00K.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $70.00K, a 88.24% decline year-over-year.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2025 was -$55.00K.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$85.00K, a 112.71% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $669.00K.
- PMV PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$367.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$67.00K 10-Q · filed 2026-08-14 | -$166.00K 10-Q · filed 2026-08-14 | -$173.00K derived: sum of 3 quarters · filed 2026-08-14 | -$103.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$99.00K 10-Q · filed 2026-05-12 | -$106.00K derived: sum of 2 quarters · filed 2026-05-12 | -$36.00K derived: sum of 3 quarters · filed 2026-05-12 | -$99.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $63.00K derived: sum of 2 quarters · filed 2026-03-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | -$55.00K 10-K · filed 2026-03-06 |
| 2025-09-30 | $70.00K 10-Q · filed 2025-11-12 | $7.00K derived: sum of 2 quarters · filed 2026-08-14 | -$48.00K 10-Q · filed 2025-11-12 | -$319.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$63.00K 10-Q · filed 2026-08-14 | -$117.00K 10-Q · filed 2026-08-14 | -$389.00K derived: sum of 3 quarters · filed 2026-08-14 | $206.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$55.00K 10-Q · filed 2026-05-12 | -$326.00K derived: sum of 2 quarters · filed 2026-05-12 | $269.00K derived: sum of 3 quarters · filed 2026-05-12 | $213.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $324.00K derived: sum of 2 quarters · filed 2026-03-06 | $268.00K derived: sum of 3 quarters · filed 2026-03-06 | -$85.00K 10-K · filed 2026-03-06 |
| 2024-09-30 | $595.00K 10-Q · filed 2025-11-12 | $539.00K derived: sum of 2 quarters · filed 2025-11-12 | $186.00K 10-Q · filed 2025-11-12 | $765.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | -$56.00K 10-Q · filed 2025-08-07 | -$408.00K 10-Q · filed 2025-08-07 | $170.00K derived: sum of 3 quarters · filed 2026-03-06 | $143.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | -$353.00K 10-Q · filed 2025-05-09 | $226.00K derived: sum of 2 quarters · filed 2026-03-06 | $199.00K derived: sum of 3 quarters · filed 2026-03-06 | -$13.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $579.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $552.00K derived: sum of 2 quarters · filed 2026-03-06 | $340.00K derived: sum of 3 quarters · filed 2026-03-06 | $669.00K 10-K · filed 2026-03-06 |
| 2023-09-30 | -$27.00K 10-Q · filed 2024-11-07 | -$239.00K derived: sum of 2 quarters · filed 2024-11-07 | $90.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$212.00K 10-Q · filed 2024-08-08 | $117.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $329.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$367.00K 10-K · filed 2025-03-03 | |||
| 2021-12-31 | -$78.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |